Drug intelligence / Profile preview

MK-0557 + orlistat

Development stage: Discontinued
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

MK-0557 + orlistat is a combination therapy that was investigated for weight management in obese patients. MK-0557 is a neuropeptide Y5 receptor (NPY5R) antagonist that targets central counter-regulatory mechanisms related to the orexigenic hormone neuropeptide Y. Orlistat is a pancreatic lipase inhibitor that reduces the absorption of dietary fat in the intestine. The combination was studied to determine if NPY5R antagonism could enhance the weight loss efficacy of orlistat.

Brand names: xenicalalli
Other names: orlistat

Targets

PNLIP (Pancreatic triacylglycerol lipase)NPY5R (Neuropeptide Y receptor type 5)

Beyond the preview

Go deeper on MK-0557 + orlistat.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-0557 + orlistat.

Explore the full profile